the market?
Vertex Pharmaceuticals
NASDAQ: VRTX
78.48
0.05
(0.06%)
Extended Hours:
$78.19
-$0.29
(-0.37%)
| Today's Open | $78.19 |
|---|---|
| Previous Close | $78.43 |
| Daily Range | $77.16 - $79.47 |
| 52-Week Range | $38.44 - $87.47 |
| Market Cap | $17.4B |
| P/E Ratio | -33.23 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 1,615,328 |
| Average Daily Volume | 3,427,473 |
| Current FY EPS | -$2.13 |
How do you think VRTX
will perform against the market?
Top VRTX Bull/Bear Pitches
mfgd (< 20)
Submitted
April 28, 2011
Vertex (VRTX) shares have been halted as an FDA advisory panel will review its telaprevir NDA today 7:05 am ET 04/28/2011- Sounds like GOOD NEWS!
zzlangerhans (< 20)
Submitted
April 15, 2008
I won't spend much time knocking telaprevir or the rest of the pipeline, as it seems there's a lot of potential there. But a market cap of 3.6 billion? In this environment for biotech? With a quarterl … More
News & Commentary
2 Scariest Dividend Stocks in Health Care
The yields look great, but these 2 health-care dividend stocks could be the scariest ones around in the near future.Racing Toward the Next Hepatitis C Drug Approval
Johnson & Johnson jumps ahead of Gilead Sciences in the race to bring next-generation hepatitis C drugs to market.3 Investment Strategy Lessons From Vertex's Success
Can you develop an investment strategy based on a biotech success story? Here are 3 lessons that show how it can be done.Don't Worry for a Second About Gilead's Earnings Miss
Gilead missed revenue and earnings estimates. But don't fret -- the biotech played a trump card.Sector
Healthcare
Industry
Drugs
Vertex Pharmaceuticals (VRTX) Description
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Website: http://www.vrtx.com/
CEO Rating by Glassdoor
More details for Vertex Pharmaceuticals Jobs
Vertex Pharmaceuticals reviews from employees
